View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 30, 2020updated 12 Jul 2022 11:44am

India’s first Covid-19 vaccine by Bharat Biotech to enter trials

India-based biotechnology company Bharat Biotech has secured regulatory approval from the Drug Controller General of India (DCGI) to advance its Covid-19 vaccine candidate, Covaxin, into human clinical trials.

India-based biotechnology company Bharat Biotech has secured regulatory approval from the Drug Controller General of India (DCGI) to advance its Covid-19 vaccine candidate, Covaxin, into human clinical trials.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

This marks the first regulatory approval for India’s domestic vaccine to enter trials. DCGI’s approval will enable the company to conduct Phase I and II studies, which are set to begin next month.

Covaxin has been developed in partnership with the Indian Council of Medical Research’s National Institute of Virology. The inactivated vaccine was manufactured in Bharat Biotech’s facility at Genome Valley in Hyderabad, India.

Bharat Biotech chairman and managing director Krishna Ella said: “We are proud to announce ‘Covaxin’, India’s first indigenous vaccine against Covid-19.

“The collaboration with ICMR and NIV was instrumental in the development of this vaccine. The proactive support and guidance from CDSCO has enabled approvals to this project.”

In April this year, Bharat Biotech partnered with FluGen and University of Wisconsin–Madison (UWMadison) to develop and evaluate a Covid-19 vaccine candidate, CoroFlu.

CoroFlu will be administered intranasally with an aim to induce multiple immune responses.

Later in May, Bharat Biotech entered into an exclusive agreement to develop a Covid-19 vaccine candidate created at Thomas Jefferson University in Philadelphia, US.

Thomas Jefferson professor developed this vaccine candidate in January using an existing deactivated rabies vaccine as a vehicle for coronavirus proteins.

Apart from Bharat Biotech, multiple companies in India are working to develop a Covid-19 vaccine, including Zydus Cadila, Serum Institute of India (SII) and Panacea Biotec. Currently, these candidates are in preclinical development stage.

In addition, SII entered a licensing agreement with AstraZeneca for one billion doses of a Covid-19 vaccine developed by the University of Oxford. AstraZeneca agreed to supply 400 million doses before the end of this year.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena